HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Two-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitors.

Abstract
Plasmodium parasites, the causative agents of malaria, have developed resistance to most of our current antimalarial therapies, including artemisinin combination therapies which are widely described as our last line of defense. Antimalarial agents with a novel mode of action are urgently required. Two Plasmodium falciparum aminopeptidases, PfA-M1 and PfA-M17, play crucial roles in the erythrocytic stage of infection and have been validated as potential antimalarial targets. Using compound-bound crystal structures of both enzymes, we have used a structure-guided approach to develop a novel series of inhibitors capable of potent inhibition of both PfA-M1 and PfA-M17 activity and parasite growth in culture. Herein we describe the design, synthesis, and evaluation of a series of hydroxamic acid-based inhibitors and demonstrate the compounds to be exciting new leads for the development of novel antimalarial therapeutics.
AuthorsShailesh N Mistry, Nyssa Drinkwater, Chiara Ruggeri, Komagal Kannan Sivaraman, Sasdekumar Loganathan, Sabine Fletcher, Marcin Drag, Alessandro Paiardini, Vicky M Avery, Peter J Scammells, Sheena McGowan
JournalJournal of medicinal chemistry (J Med Chem) Vol. 57 Issue 21 Pg. 9168-83 (Nov 13 2014) ISSN: 1520-4804 [Electronic] United States
PMID25299353 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimalarials
  • Hydroxamic Acids
  • Protease Inhibitors
  • Protozoan Proteins
  • Aminopeptidases
Topics
  • Aminopeptidases (antagonists & inhibitors)
  • Antimalarials (chemical synthesis, pharmacology)
  • Cell Survival (drug effects)
  • HEK293 Cells (drug effects)
  • Humans
  • Hydroxamic Acids (chemical synthesis, pharmacology)
  • Models, Molecular
  • Plasmodium falciparum (enzymology)
  • Protease Inhibitors (chemical synthesis, pharmacology)
  • Protozoan Proteins (antagonists & inhibitors)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: